Carmell Corp. Hits New 52-Week Low at $1.21 Amidst Declining Performance

Carmell Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.21 as of September 15, 2025. This significant decline reflects a challenging year for the company, which has seen its stock price plummet by 48% over the past year, starkly contrasting with the S&P 500's performance of 17.67% during the same period.
The company's financial metrics reveal a concerning picture. With a market capitalization of just USD 4 million, Carmell Corp. is classified as a microcap stock. It has reported negative earnings, resulting in a lack of a price-to-earnings ratio, and its price-to-book ratio stands at -1.20, indicating a negative book value. Additionally, the company has a debt-to-equity ratio of 0.39, suggesting some leverage, but its ability to service this debt is questionable, as evidenced by a poor EBIT to interest ratio of -2.99.

Carmell Corp.'s recent performance has been marked by consistent losses, with the latest operating profit reported at USD -1.79 million. The company's promoters have also reduced their stake by over 20%, which may reflect waning confidence in its future prospects. Overall, the stock's trajectory continues to raise concerns among market observers.